European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.

The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the ...

Lundbeck, una farmacéutica global con sede en Dinamarca, ha acordado comprar Longboard Pharmaceuticals, con sede en La Jolla, ...

Lundbeck, a global drugmaker based in Denmark, has agreed to buy La Jolla-based Longboard Pharmaceuticals for $2.6 billion to ...

Fintel reports that on October 15, 2024, HC Wainwright & Co. downgraded their outlook for Longboard Pharmaceuticals (NasdaqGM ...

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Longboard Pharmaceuticals (LBPH – Research ...

Lundbeck’s acquisition of Longboard Pharmaceuticals is meant to bolster its neuro-rare disease franchise, the drugmaker ...

Lundbeck, a biopharmaceutical company based in Denmark, has announced the acquisition of Longboard Pharmaceuticals in a ...

Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion. Read more on ...

On Monday, Longboard Pharmaceuticals Inc (LBPH) stock saw a modest uptick, ending the day at $58.99 which represents a slight increase of $20.09 or 51.65% from the prior close of $38.9. The stock ...

(Reuters) -H Lundbeck A/S has agreed to buy U.S.-based Longboard Pharmaceuticals for $2.6 billion, marking the biggest deal ...